MET and non-small cell lung carcinoma: (60), among 43 NSCLC patients who developed resistance to erlotinib or gefitinib treatment, 9 cases (21%) were found to have MET gene amplification, while among 62 NSCLC patients who did not receive any treatment, only 2 cases (3%) carried MET gene amplification.